INDIA – Glenmark Pharmaceuticals has announced the launch of a novel fixed-dose combination (FDC) of Teneligliptin and Pioglitazone for adults with uncontrolled Type 2 diabetes in India.

India is known to be the diabetes capital of the world. As per the International Diabetes Federation (IDF), the prevalence of diabetes in India is around 74 million adults, out of these, 77 percent of patients have controlled diabetes.

The number is expected to increase to 125 million, representing nearly 70 percent increase by 2045.

According to a company statement, Glenmark has launched this FDC under the brand name Zita Plus Pio, which contains Teneligliptin (20 mg) and Pioglitazone (15 mg) and is to be taken once daily.

Diabetes is a key area of focus for Glenmark, which has been a pioneer in providing diabetic patients in India with access to the most up-to-date treatment options.

In 2015, Glenmark revolutionized the diabetes market by launching its DPP4 inhibitor – Teneligliptin in India, followed by an FDC of Teneligliptin + Metformin.

Glenmark has a strong legacy of more than four decades of progress and innovation. In continuation towards its first time in India legacy, it launched FDC of Teneligliptin + Remogliflozin in 2021.

Glenmark Pharmaceuticals Group Vice President & Head, India Formulations Alok Malik said, “We are delighted to introduce this novel Zita Plus Pio, which is the first of its kind in India; offering a world-class and affordable treatment option to adult diabetic patients.”

Glenmark asserted that it is the “first company in India to market the innovative FDC of Teneligliptin + Pioglitazone, which has been approved by the DCGI (Drug Controller General of India).”

The innovative Fixed-Dose Combination will help improving the glycemic control among adult patients with insulin resistance, those whose diabetes is uncontrolled by metformin; and also, those who require addition of Teneliglitptin and Pioglitazone as separate drugs.

In Type 2 diabetes, the body’s ability to regulate sugar is impaired, primarily due to cells responding poorly to insulin, resulting in a high level of sugar circulating in the bloodstream.

Glenmark’s combination FDC of Teneliglitptin and Pioglitazone is efficacious to tackle the functional changes that accompany diabetes mellitus, which makes the drug more effective in managing uncontrolled Type 2 diabetes.

The combination of Teneligliptin + Pioglitazone will provide a synergistic approach wherein Teneligliptin will optimally improve β cell sensitivity, and Pioglitazone will effectively reduce insulin resistance.

Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE